Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:942-947
Published online before print February 2, 2006, doi: 10.1161/01.ATV.0000208365.45200.41
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
26/4/942    most recent
01.ATV.0000208365.45200.41v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Auro, K.
Right arrow Articles by Salomaa, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Auro, K.
Right arrow Articles by Salomaa, V.
Related Collections
Right arrow Acute myocardial infarction
Right arrow Acute Cerebral Infarction
Right arrow Epidemiology
Right arrow Genetics of cardiovascular disease
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:942.)
© 2006 American Heart Association, Inc.


Thrombosis

Thrombomodulin Gene Polymorphisms and Haplotypes and the Risk of Cardiovascular Events

A Prospective Follow-Up Study

K. Auro; K. Komulainen; M. Alanne; K. Silander; L. Peltonen; M. Perola; V. Salomaa

From the Department of Molecular Medicine (K.A., K.K., M.A., K.S., L.P., M.P.), KTL, Helsinki, Finland; Department of Epidemiology and Health Promotion (V.S.), KTL, Helsinki, Finland; and Department of Medical Genetics (L.P., M.P.), University of Helsinki, Finland.

Correspondence to Dr Veikko Salomaa, Department of Epidemiology and Health Promotion, KTL-National Public Health Institute Mannerheimintie 166, FI-00300 Helsinki Finland. E-mail veikko.salomaa{at}ktl.fi

Background— Thrombomodulin is an anticoagulant expressed during endothelial activation and damage. To address the potential role of allelic variants of thrombomodulin gene in the pathogenesis of cardiovascular diseases, we analyzed in a prospective follow-up study 8 single-nucleotide polymorphisms (SNPs) across the thrombomodulin locus, covering all common (>5%) haplotypes.

Methods and Results— Two separate, stratified random samples of men and women 25 to 74 years of age were examined in Finland in 1992 and 1997. The total sample size was 14 140 individuals, with 7 (1997 cohort) to 10 (1992 cohort) years of follow-up. Altogether, 662 individuals had a history of cardiovascular events already at baseline. During the follow-up, 401 incident coronary events and 148 incident ischemic strokes were observed. The alleles and common haplotypes of 8 SNPs were tested in Cox proportional hazards models using incident coronary events, incident ischemic strokes, and total mortality as end points. None of the SNPs or major SNP haplotypes showed consistent association with the end points analyzed in the combined data.

Conclusions— Results from this prospective, population-based study suggest that common allelic variants of the thrombomodulin gene may not significantly contribute to the risk of cardiovascular events at the population level.

Thrombomodulin, a natural anticoagulant and a biological marker for endothelial activation and damage, has been suggested to contribute to the pathogenesis of cardiovascular diseases. In a prospective follow-up study combining 2 large, independent Finnish cohorts, common allelic variants of the thrombomodulin gene did not show consistent association with the risk of cardiovascular events.


Key Words: coronary artery disease • stroke • thrombosis • genetic mutations • epidemiology